JPWO2014171507A1 - Emulsified composition - Google Patents

Emulsified composition Download PDF

Info

Publication number
JPWO2014171507A1
JPWO2014171507A1 JP2015512517A JP2015512517A JPWO2014171507A1 JP WO2014171507 A1 JPWO2014171507 A1 JP WO2014171507A1 JP 2015512517 A JP2015512517 A JP 2015512517A JP 2015512517 A JP2015512517 A JP 2015512517A JP WO2014171507 A1 JPWO2014171507 A1 JP WO2014171507A1
Authority
JP
Japan
Prior art keywords
emulsified composition
ceresin
mass
composition
emulsified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015512517A
Other languages
Japanese (ja)
Inventor
真由美 緒方
真由美 緒方
明子 佐近
明子 佐近
有紀子 松土
有紀子 松土
堀 聖一
聖一 堀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of JPWO2014171507A1 publication Critical patent/JPWO2014171507A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/06Emulsions
    • A61K8/064Water-in-oil emulsions, e.g. Water-in-silicone emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31Hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/345Alcohols containing more than one hydroxy group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39Derivatives containing from 2 to 10 oxyalkylene groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

(a)モノオレイン酸ポリグリセリル、(b)グリセリン、(c)セレシン、及び(d)水を含有することを特徴とする乳化組成物は、経時的な分離が抑えられ、性状安定性に優れた乳化組成物であり、医薬品・医薬部外品・化粧品等の乳化組成物として有用である。本乳化組成物はさらに、流動パラフィン、スクワラン、白色ワセリン等の油性成分を含んでもよく、好ましくはW/O型である。典型的には、乳化組成物全質量に対し0.1〜20質量%のセレシン、0.5〜40質量%のモノオレイン酸ポリグリセリルを含み、セレシン対モノオレイン酸ポリグリセリルの質量比は好ましくは、0.1〜5:1である。The emulsion composition characterized by containing (a) polyglyceryl monooleate, (b) glycerin, (c) ceresin, and (d) water is excellent in property stability because separation with time is suppressed. The emulsified composition is useful as an emulsified composition for pharmaceuticals, quasi drugs, cosmetics, and the like. The emulsified composition may further contain an oily component such as liquid paraffin, squalane and white petrolatum, and is preferably W / O type. Typically, it contains 0.1 to 20% by weight of ceresin, 0.5 to 40% by weight of polyglyceryl monooleate with respect to the total weight of the emulsion composition, and the weight ratio of ceresin to polyglyceryl monooleate is preferably 0.1-5: 1.

Description

本発明は、経時的な分離を抑制し、性状安定性を向上させた乳化組成物に関する。   The present invention relates to an emulsified composition that suppresses separation with time and improves property stability.

乳化組成物はO/W型とW/O型に大別されている。W/O型乳化組成物は、外相が油、内相が水で構成されているため、水をはじきやすく、患部を保護する作用があるが、軟膏剤のようなべたつきがない製剤である。このように、W/O型乳化組成物は使用感が良いため、医薬品や化粧品分野における幅広い活用が期待される。一方、W/O型乳化組成物の安定性に関しては、内水相から経時的に水の分離(製剤からの水の浸み出し)が起こりやすいという課題がある。特に、さっぱりとした使用感を付与するため、内水相の水の含量を多くした場合には、より一層、分離が生じやすい。
従来、W/O型乳化組成物の安定性を向上する方法として、液状油性基剤に液状油性成分のゲル化剤を加えてゲル化させ、特定の油中水型界面活性剤によりゲル化させた水と混合して乳化させる方法が知られている(特許文献1)。しかし、上記W/O型乳化組成物はゲル化剤としてデキストリン脂肪酸エステルのような油性ゲル化剤を用いるため、べたつきが生じ、使用感の面で課題がある。
The emulsified compositions are roughly classified into O / W type and W / O type. The W / O type emulsified composition is composed of an oil as an outer phase and water as an inner phase, so that it easily repels water and protects an affected area, but does not have stickiness like an ointment. As described above, since the W / O emulsion composition has a good usability, it is expected to be widely used in the pharmaceutical and cosmetic fields. On the other hand, regarding the stability of the W / O emulsion composition, there is a problem that water is likely to be separated from the inner aqueous phase with time (leaching of water from the preparation). In particular, when the content of water in the inner aqueous phase is increased in order to give a refreshing feeling of use, separation is more likely to occur.
Conventionally, as a method for improving the stability of a W / O type emulsion composition, a liquid oily base is added with a gelling agent of a liquid oily component to cause gelation, and then gelled with a specific water-in-oil surfactant. A method of emulsifying by mixing with water is known (Patent Document 1). However, since the W / O emulsion composition uses an oily gelling agent such as a dextrin fatty acid ester as a gelling agent, stickiness occurs, and there is a problem in terms of usability.

今までに、モノオレイン酸グリセリンとアルキル基に分岐鎖を有する界面活性剤を用いることにより、高含水のW/O型乳化組成物が報告されているが(特許文献2)、グリセリンと、任意選択的に流動パラフィン、スクワラン、白色ワセリンとを配合し、モノオレイン酸ポリグリセリルを乳化剤とするW/O型乳化組成物について、セレシンを配合して経時的な分離が抑制された例は報告されていない。   So far, a high water content W / O emulsion composition has been reported by using a glyceryl monooleate and a surfactant having a branched chain in the alkyl group (Patent Document 2). Regarding W / O type emulsified composition containing liquid paraffin, squalane and white petrolatum selectively and emulsifying polyglyceryl monooleate as an emulsifier, there has been reported an example where ceresin was blended to prevent separation over time. Absent.

特許3509108号Patent 3509108 特開2007−153824号公報JP 2007-153824 A

本発明は、モノオレイン酸ポリグリセリルとグリセリンを含む乳化組成物において、経時的な分離を抑制し、性状安定性に優れた乳化組成物を提供することである。   This invention is providing the emulsion composition which suppressed separation with time and was excellent in property stability in the emulsion composition containing monoglyceryl monooleate and glycerin.

本発明者は、上記課題を解決するため鋭意検討した結果、モノオレイン酸ポリグリセリルとグリセリンを含有する乳化組成物にセレシンを配合することにより、分離が生じず、長期間保存しても性状が安定な乳化組成物とすることができることを見出し、本発明を完成した。   As a result of intensive studies to solve the above-mentioned problems, the present inventor did not cause separation by blending ceresin into an emulsified composition containing polyglyceryl monooleate and glycerin, and stable in properties even after long-term storage. The present invention has been completed by finding that it can be made into an emulsified composition.

すなわち本発明は、
(1)(a)モノオレイン酸ポリグリセリル、(b)グリセリン、(c)セレシン、及び(d)水を含有することを特徴とする乳化組成物、
(2)W/O型である、(1)に記載の乳化組成物、
(3)さらに、流動パラフィン、スクワラン及び白色ワセリンからなる群から選ばれる少なくとも1種の油性成分を含む、(1)又は(2)に記載の乳化組成物、
(4)セレシンの含有量が、乳化組成物全質量に対し0.1〜20質量%である、(1)に記載の乳化組成物、
(5)モノオレイン酸ポリグリセリルの含有量が、乳化組成物全質量に対し、0.5〜40質量%である、(1)に記載の乳化組成物、
(6)セレシンの含有量が、モノオレイン酸ポリグリセリル1質量部に対し、0.1〜5質量部である、(1)に記載の乳化組成物、
である。
That is, the present invention
(1) An emulsified composition containing (a) polyglyceryl monooleate, (b) glycerin, (c) ceresin, and (d) water,
(2) The emulsion composition according to (1), which is a W / O type,
(3) The emulsion composition according to (1) or (2), further comprising at least one oily component selected from the group consisting of liquid paraffin, squalane and white petrolatum,
(4) The emulsified composition according to (1), wherein the content of ceresin is 0.1 to 20% by mass relative to the total mass of the emulsified composition,
(5) The emulsion composition according to (1), wherein the content of polyglyceryl monooleate is 0.5 to 40% by mass relative to the total mass of the emulsion composition,
(6) The emulsified composition according to (1), wherein the content of ceresin is 0.1 to 5 parts by mass with respect to 1 part by mass of polyglyceryl monooleate,
It is.

本発明により、分離を抑制し、性状安定性に優れ、さらに使用感も良好な乳化組成物の提供が可能となった。   According to the present invention, it is possible to provide an emulsified composition that suppresses separation, is excellent in property stability, and has a good usability.

本発明のモノオレイン酸ポリグリセリルとしては、モノオレイン酸ジグリセリル、モノオレイン酸テトラグリセリル等が挙げられ、これらの中でもモノオレイン酸ジグリセリルが好ましい。モノオレイン酸ポリグリセリルとしては、例えばNIKKOL DGMO―CV(商品名:日光ケミカルズ株式会社製)、EMALEX MOG−2(商品名:日本エマルジョン株式会社製)等の市販品を利用することもできる。モノオレイン酸ポリグリセリルの含有量は、本発明の乳化組成物全体に対して0.5〜40質量%が好ましく、さらに好ましくは1〜20質量%であり、最も好ましいのは1.5〜10質量%である。   Examples of the polyglyceryl monooleate of the present invention include diglyceryl monooleate, tetraglyceryl monooleate, and the like. Among these, diglyceryl monooleate is preferable. As polyglyceryl monooleate, commercially available products such as NIKKOL DGMO-CV (trade name: manufactured by Nikko Chemicals Co., Ltd.) and EMALEX MOG-2 (trade name: manufactured by Nippon Emulsion Co., Ltd.) can be used. The content of polyglyceryl monooleate is preferably 0.5 to 40% by mass, more preferably 1 to 20% by mass, and most preferably 1.5 to 10% by mass with respect to the whole emulsion composition of the present invention. %.

本発明のグリセリンとしては、グリセリン及び/又は濃グリセリンを用いることができ、特に制限はないが、濃グリセリンがより好ましい。このグリセリンとしてはグリセリン(商品名:阪本薬品工業製)、日本薬局方濃グリセリン(商品名:花王株式会社製)等の市販品を利用することもできる。グリセリンの含有量は、本発明の乳化組成物全体に対して5〜25質量%が好ましい。   As glycerin of the present invention, glycerin and / or concentrated glycerin can be used, and there is no particular limitation, but concentrated glycerin is more preferable. As this glycerin, commercially available products such as glycerin (trade name: manufactured by Sakamoto Yakuhin Kogyo Co., Ltd.) and Japanese Pharmacopoeia Concentrated Glycerin (trade name: manufactured by Kao Corporation) can also be used. As for content of glycerol, 5-25 mass% is preferable with respect to the whole emulsion composition of this invention.

本発明のセレシンとしては、まずオゾケライトを精製した鉱物由来の固形の炭化水素類が挙げられる。性質はパラフィンに似ているが、分子量、比重、粘度、硬度、融点などがパラフィンより高いという特徴を持つ。通常セレシンは60乃至80℃程度の融点をもつが、本発明においては融点が65℃以上のセレシンが好適である。また、本発明にいうセレシンには、上記の天然に産出されたものの他に、通常セレシンと代替可能に使用されている、マイクロクリスタリンワックスと流動パラフィンの混合物である合成パラフィンなども包含される。合成パラフィンを用いる場合であっても、その融点を60乃至80℃程度、好適には65℃以上とすることが推奨される。本発明ではセレシン#810(商品名:日興リカ株式会社)等の市販品を利用することもできる。本発明のセレシンの含有量は、本発明の乳化組成物全体に対して0.1〜20質量%が好ましく、さらに好ましくは1〜15質量%である。また、セレシンの含有量は、モノオレイン酸ポリグリセリル1質量部に対し、0.1〜5質量部が好ましい。   Examples of ceresin of the present invention include mineral-derived solid hydrocarbons obtained by purifying ozokerite. The properties are similar to paraffin, but are characterized by higher molecular weight, specific gravity, viscosity, hardness, melting point, etc. than paraffin. Normally, ceresin has a melting point of about 60 to 80 ° C., but ceresin having a melting point of 65 ° C. or more is preferred in the present invention. The ceresin referred to in the present invention includes synthetic paraffin, which is a mixture of microcrystalline wax and liquid paraffin, which is usually used as a substitute for ceresin, in addition to the above naturally produced one. Even when synthetic paraffin is used, it is recommended that its melting point is about 60 to 80 ° C., preferably 65 ° C. or higher. In the present invention, commercially available products such as ceresin # 810 (trade name: Nikko Rika Co., Ltd.) can also be used. 0.1-20 mass% is preferable with respect to the whole emulsion composition of this invention, and, as for content of the ceresin of this invention, More preferably, it is 1-15 mass%. Moreover, the content of ceresin is preferably 0.1 to 5 parts by mass with respect to 1 part by mass of polyglyceryl monooleate.

本発明の乳化組成物には、油性成分である流動パラフィン、スクワラン、又は白色ワセリンを配合することが好ましい。
流動パラフィンとしては、ハイコールM−352(商品名:カネダ株式会社製)等の市販品を利用することもできる。流動パラフィンの含有量は、本発明の乳化組成物全体に対して1〜30質量%が好ましく、5〜30質量%が特に好ましい。
The emulsified composition of the present invention preferably contains oily components such as liquid paraffin, squalane, or white petrolatum.
As the liquid paraffin, commercially available products such as HICOAL M-352 (trade name: manufactured by Kaneda Corporation) can be used. 1-30 mass% is preferable with respect to the whole emulsion composition of this invention, and, as for content of a liquid paraffin, 5-30 mass% is especially preferable.

本発明のスクワランとしては、スクワラン−SK(商品名:株式会社クラレ製)等の市販品を利用することもできる。スクワランの含有量は、本発明の乳化組成物全体に対して0.1〜20質量%が好ましく、さらに好ましくは0.5〜10質量%が好ましく、さらに好ましくは1〜10質量%である。   As the squalane according to the present invention, a commercially available product such as squalane-SK (trade name: manufactured by Kuraray Co., Ltd.) can be used. The content of squalane is preferably 0.1 to 20% by mass, more preferably 0.5 to 10% by mass, and further preferably 1 to 10% by mass with respect to the entire emulsion composition of the present invention.

本発明の白色ワセリンとしては、白色ワセリン(商品名:PENRECO社製)等の市販品を利用することもできる。白色ワセリンの含有量は、本発明の乳化組成物全体に対して0.1〜20質量%が好ましく、さらに好ましくは0.5〜10質量%である。   As white petrolatum of the present invention, commercial products such as white petrolatum (trade name: manufactured by PENRECO) can be used. 0.1-20 mass% is preferable with respect to the whole emulsion composition of this invention, and, as for content of white petrolatum, More preferably, it is 0.5-10 mass%.

また、本発明の乳化組成物は、好ましくはW/O型乳化組成物であり、剤型としてはクリーム、乳液等が挙げられる。本発明の乳化組成物は、医薬品、医薬部外品、化粧品などに適用可能である。   The emulsified composition of the present invention is preferably a W / O type emulsified composition, and examples of the dosage form include creams and emulsions. The emulsified composition of the present invention is applicable to pharmaceuticals, quasi drugs, cosmetics and the like.

本発明の乳化組成物中の水の含有量は、本発明の乳化組成物全体に対して1〜70質量%が好ましく、より好ましくは20〜70質量%である。また、本発明においては、本発明の組成物中に50質量%以上の水を含んでいても、分離の生じないW/O型乳化組成物の調製が可能である。   1-70 mass% is preferable with respect to the whole emulsion composition of this invention, and, as for content of the water in the emulsion composition of this invention, More preferably, it is 20-70 mass%. Moreover, in this invention, even if it contains 50 mass% or more of water in the composition of this invention, preparation of the W / O type | mold emulsion composition which does not produce a separation is possible.

本発明の乳化組成物には、本発明の効果を損なわない範囲でその使用目的に応じて、使用目的に応じた薬物あるいは化粧品に配合できる成分を配合することができる。薬物を配合する場合は、薬物の種類によって、創傷治癒や消炎鎮痒、口内炎、痔疾患などに広範に適用することが可能である。
本発明の乳化組成物に配合できる薬物としては、特に制限ないが、例えばイソプロピルメチルフェノール、塩酸クロルヘキシジン、塩化ベンゼトニウム、塩化ベンザルコニウム、塩化デカリニウム、ヒノキチオールなどの殺菌剤、アラントインなどの創傷治癒剤、塩酸ジフェンヒドラミン、ジフェンヒドラミン、マレイン酸クロルフェニラミンなどの抗ヒスタミン剤、酢酸ヒドロコルチゾン、酢酸プレドニゾロン、ヒドロコルチゾン、プレドニゾロン、プロピオン酸デキサメタゾン、プロピオン酸ベタメタゾン、吉草酸デキサメタゾン、吉草酸ベタメタゾン、フルオシノロンアセトニド、トリアムシノロンアセトニドなどのステロイド剤が挙げられる。その他の成分として、ジブチルヒドロキシトルエン、イソプロピルガレート、エデト酸塩などの抗酸化剤、メントール、カンフルなどの清涼化剤、パラベン、安息香酸塩、デヒドロ酢酸、エリソルビン酸、ソルビン酸などの防腐剤、クエン酸、クエン酸塩などのpH調節剤、色素、香料などが配合できる。なお、これまでに記載した成分について限定されるものではない。
In the emulsified composition of the present invention, components that can be blended in drugs or cosmetics according to the purpose of use can be blended according to the purpose of use within the range not impairing the effects of the present invention. When a drug is blended, it can be widely applied to wound healing, anti-inflammatory antiseptic, stomatitis, hemorrhoid disease, etc., depending on the type of drug.
The drug that can be blended in the emulsified composition of the present invention is not particularly limited, for example, bactericides such as isopropylmethylphenol, chlorhexidine hydrochloride, benzethonium chloride, benzalkonium chloride, decalinium chloride, hinokitiol, wound healing agents such as allantoin, Antihistamines such as diphenhydramine hydrochloride, diphenhydramine, chlorpheniramine maleate, hydrocortisone acetate, prednisolone acetate, hydrocortisone, prednisolone, dexamethasone propionate, betamethasone propionate, dexamethasone valerate, betamethasone valerate, fluocinolone acetonide acetonide Steroids. Other ingredients include antioxidants such as dibutylhydroxytoluene, isopropyl gallate and edetate, refreshing agents such as menthol and camphor, parabens, benzoates, preservatives such as dehydroacetic acid, erythorbic acid and sorbic acid, PH adjusting agents such as acids and citrates, pigments, and fragrances can be blended. In addition, it is not limited about the component described until now.

本発明の乳化組成物の製造方法は、特に限定されるものではない。通常、それぞれの成分を適切な製造機で均一な乳液状又はペースト状の乳化組成物となるように混合して製造することができる。   The manufacturing method of the emulsion composition of this invention is not specifically limited. Usually, it can manufacture by mixing each component so that it may become a uniform emulsion or paste-form emulsion composition with a suitable manufacturing machine.

以下に実施例及び比較例をあげて本発明をさらに詳細に説明するが、これらの実施例等に限定されるものではない。なお、実施例及び比較例で使用したセレシンはセレシン#810(商品名:日興リカ株式会社 融点72〜76℃)、パラフィンはパラフィンワックス135(商品名:日本精蝋 融点55〜62℃)である。   Hereinafter, the present invention will be described in more detail with reference to examples and comparative examples, but the present invention is not limited to these examples. In addition, the ceresin used by the Example and the comparative example is ceresin # 810 (brand name: Nikko Rika Co., Ltd. melting point 72-76 degreeC), and a paraffin is paraffin wax 135 (brand name: Nippon Seiwa wax melting point 55-62 degreeC). .

実施例1〜6、比較例1〜2
(各乳化組成物の調製法)
下記の表1に示す処方に従い、各成分を秤量し、モノオレイン酸ジグリセリル、流動パラフィン、スクワラン、固形脂(セレシン、パラフィン又はモノステアリン酸グリセリン)、白色ワセリンからなる油相を約80℃に加温し、溶融した。濃グリセリン及び適宜精製水を加えて水相とし、約80℃に加温後、ホモミキサーをかけながら油相に添加した。攪拌後、冷却して実施例1〜6、及び比較例1、2のW/O型乳化組成物を得た。
Examples 1-6, Comparative Examples 1-2
(Preparation method of each emulsified composition)
According to the formulation shown in Table 1 below, each component was weighed, and an oil phase consisting of diglyceryl monooleate, liquid paraffin, squalane, solid fat (ceresin, paraffin or glyceryl monostearate), white petrolatum was brought to about 80 ° C. Warmed and melted. Concentrated glycerin and appropriately purified water were added to form an aqueous phase, heated to about 80 ° C., and then added to the oil phase while applying a homomixer. After stirring, the mixture was cooled to obtain W / O type emulsion compositions of Examples 1 to 6 and Comparative Examples 1 and 2.

Figure 2014171507
Figure 2014171507

(試験例1)
実施例1及び比較例1、2の乳化組成物を50℃にて2ヶ月保存後、各製剤の性状を以下の評価基準に基づいて評価した。
(Test Example 1)
After the emulsion compositions of Example 1 and Comparative Examples 1 and 2 were stored at 50 ° C. for 2 months, the properties of each preparation were evaluated based on the following evaluation criteria.

評価基準
○:分離なし
×:分離あり
結果を表1に示す。
Evaluation criteria ○: No separation ×: With separation The results are shown in Table 1.

Figure 2014171507
Figure 2014171507

表1から明らかなように、セレシンを配合した実施例1は、50℃2ヶ月保存後でも製剤の分離等、性状の変化が認められなかった。これに対し、他の固形脂であるパラフィンまたはモノステアリン酸グリセリンを配合した比較例1及び2は製剤の分離が生じた。   As is clear from Table 1, Example 1 containing ceresin showed no change in properties such as separation of the preparation even after storage at 50 ° C. for 2 months. In contrast, Comparative Examples 1 and 2 containing other solid fats such as paraffin or glyceryl monostearate caused separation of the preparations.

(試験例2)
実施例1〜6及び比較例1〜2の乳化組成物を、2700rpmで遠心分離を行い、安定性を評価した。乳化組成物が分離し始めるまでの時間を以下の評価基準で評価した。
(Test Example 2)
The emulsion compositions of Examples 1 to 6 and Comparative Examples 1 and 2 were centrifuged at 2700 rpm, and the stability was evaluated. The time until the emulsified composition began to separate was evaluated according to the following evaluation criteria.

評価基準
◎:6時間以内に分離しなかった。
○:0.5〜6時間未満に分離し始めた。
×:0.5時間未満に分離し始めた。
結果を表3に示す。
Evaluation Criteria A: Not separated within 6 hours.
○: Separation began within 0.5 to less than 6 hours.
X: Separation started in less than 0.5 hours.
The results are shown in Table 3.

Figure 2014171507
Figure 2014171507

比較例3
下記の表4に示す処方に従い、各成分を秤量し、モノイソステアリン酸ジグリセリル、流動パラフィン、スクワラン、固形脂(セレシン、パラフィン又はモノステアリン酸グリセリン)、白色ワセリンからなる油相を約80℃に加温し、溶融した。濃グリセリン及び適宜精製水を加えて水相とし、約80℃に加温後、ホモミキサーをかけながら油相に添加した。攪拌後、冷却して比較例3のW/O型乳化組成物を得た。
Comparative Example 3
According to the formulation shown in Table 4 below, each component was weighed, and an oil phase consisting of diglyceryl monoisostearate, liquid paraffin, squalane, solid fat (ceresin, paraffin or glyceryl monostearate), white petrolatum was brought to about 80 ° C. Warmed and melted. Concentrated glycerin and appropriately purified water were added to form an aqueous phase, heated to about 80 ° C., and then added to the oil phase while applying a homomixer. After stirring, the mixture was cooled to obtain a W / O type emulsion composition of Comparative Example 3.

Figure 2014171507
Figure 2014171507

(試験例3:使用感試験)
実施例1及び比較例3の乳化組成物について、展延性を評価した。25℃における3分後の展延性をスプレッドメーター(離合社製)にて測定した。その結果、実施例1の乳化組成物は35.5mmであったのに対し、比較例3は26.5mmであった。したがって、本発明の乳化組成物は、他の界面活性剤を使用したものと比較して延びが良く、使用感が良いことが分かった。
(Test Example 3: Usability test)
About the emulsified composition of Example 1 and Comparative Example 3, the spreadability was evaluated. The spreadability after 3 minutes at 25 ° C. was measured with a spread meter (manufactured by Kogaisha). As a result, the emulsion composition of Example 1 was 35.5 mm, while Comparative Example 3 was 26.5 mm. Therefore, it was found that the emulsified composition of the present invention has a longer elongation and a better feeling when used than other surfactants.

実施例7、比較例4〜5
(乳化組成物の調製法)
下記の表5に示す処方に従い、各成分を秤量し、モノオレイン酸ジグリセリル、流動パラフィン、スクワラン、セレシン、白色ワセリンからなる油相を約80℃に加温し、溶融する。濃グリセリン及び適宜精製水を加えて水相とし、塩化ベンゼトニウム、マレイン酸クロルフェニラミン、アラントインを添加後、約80℃に加温して溶解させた。ホモミキサーをかけながら油相に水相を添加した。攪拌後、冷却して実施例7及び比較例4、5の乳化組成物を得た。
Example 7, Comparative Examples 4-5
(Preparation method of emulsified composition)
According to the formulation shown in Table 5 below, each component is weighed, and an oil phase composed of diglyceryl monooleate, liquid paraffin, squalane, ceresin and white petrolatum is heated to about 80 ° C. and melted. Concentrated glycerin and appropriately purified water were added to form an aqueous phase, and after adding benzethonium chloride, chlorpheniramine maleate, and allantoin, the mixture was heated to about 80 ° C. and dissolved. The water phase was added to the oil phase while applying the homomixer. After stirring, the mixture was cooled to obtain emulsified compositions of Example 7 and Comparative Examples 4 and 5.

(試験例4)
実施例7及び比較例4、5の乳化組成物を40℃75%RH条件下にて6ヶ月保存後、各製剤の性状を以下の評価基準に基づいて評価した。
(Test Example 4)
After the emulsion compositions of Example 7 and Comparative Examples 4 and 5 were stored for 6 months under 40 ° C. and 75% RH conditions, the properties of each preparation were evaluated based on the following evaluation criteria.

評価基準
○:分離なし
×:分離あり
結果を表6に示す。
Evaluation criteria ○: No separation ×: With separation The results are shown in Table 6.

Figure 2014171507
Figure 2014171507

Figure 2014171507
Figure 2014171507

セレシンを配合した実施例7は40℃75%RHで6ヶ月まで分離を起こさず、安定な性状を維持した。他の固形脂であるパラフィンまたはモノステアリン酸グリセリンを配合した比較例4、5では分離が認められた。   Example 7 containing ceresin did not cause separation until 6 months at 40 ° C. and 75% RH, and maintained stable properties. In Comparative Examples 4 and 5 in which other solid fats such as paraffin or glyceryl monostearate were blended, separation was observed.

(実施例8〜10、比較例6)
(各乳化組成物の調製法)
下記の表7に示す処方に従い、各成分を秤量し、モノオレイン酸ジグリセリル、流動パラフィン、スクワラン、固形脂(セレシン、又はモノステアリン酸グリセリン)、白色ワセリンからなる油相を約80℃に加温し、溶融した。濃グリセリン及び適宜精製水を加えて水相とし、約80℃に加温後、ホモミキサーをかけながら油相に添加した。攪拌後、冷却して実施例8〜10、及び比較例6のW/O型乳化組成物を得た。
実施例8〜10及び比較例6の乳化組成物を、2700rpmで遠心分離を行い、試験例2と同じ評価基準で乳化組成物が分離し始めるまでの時間を評価した。結果を表7に示す。
(Examples 8 to 10, Comparative Example 6)
(Preparation method of each emulsified composition)
Each component was weighed according to the formulation shown in Table 7 below, and an oil phase consisting of diglyceryl monooleate, liquid paraffin, squalane, solid fat (ceresin or glyceryl monostearate), and white petrolatum was added to about 80 ° C. Warm and melt. Concentrated glycerin and appropriately purified water were added to form an aqueous phase, heated to about 80 ° C., and then added to the oil phase while applying a homomixer. After stirring, the mixture was cooled to obtain W / O type emulsion compositions of Examples 8 to 10 and Comparative Example 6.
The emulsified compositions of Examples 8 to 10 and Comparative Example 6 were centrifuged at 2700 rpm, and the time until the emulsified composition started to be separated was evaluated according to the same evaluation criteria as in Test Example 2. The results are shown in Table 7.

Figure 2014171507
Figure 2014171507

本発明により、経時的な分離を抑え、性状安定性に優れた乳化組成物の提供が可能となった。本乳化組成物は、医薬品・医薬部外品・化粧品等の乳化組成物として有用である。   According to the present invention, it is possible to provide an emulsified composition that suppresses separation with time and is excellent in property stability. The emulsified composition is useful as an emulsified composition for pharmaceuticals, quasi drugs, cosmetics and the like.

Claims (6)

(a)モノオレイン酸ポリグリセリル、(b)グリセリン、(c)セレシン、及び(d)水を含有することを特徴とする乳化組成物。   An emulsified composition comprising (a) polyglyceryl monooleate, (b) glycerin, (c) ceresin, and (d) water. W/O型である、請求項1に記載の乳化組成物。   The emulsified composition according to claim 1, which is W / O type. さらに、流動パラフィン、スクワラン及び白色ワセリンからなる群から選ばれる少なくとも1種の油性成分を含む、請求項1又は2に記載の乳化組成物。   Furthermore, the emulsion composition of Claim 1 or 2 containing the at least 1 sort (s) of oily component chosen from the group which consists of a liquid paraffin, squalane, and white petrolatum. セレシンの含有量が、乳化組成物全質量に対し0.1〜20質量%である、請求項1に記載の乳化組成物。   The emulsified composition according to claim 1, wherein the content of ceresin is 0.1 to 20% by mass relative to the total mass of the emulsified composition. モノオレイン酸ポリグリセリルの含有量が、乳化組成物全質量に対し、0.5〜40質量%である、請求項1に記載の乳化組成物。   The emulsified composition according to claim 1, wherein the content of polyglyceryl monooleate is 0.5 to 40% by mass with respect to the total mass of the emulsified composition. セレシンの含有量が、モノオレイン酸ポリグリセリル1質量部に対し、0.1〜5質量部である、請求項1に記載の乳化組成物。   The emulsified composition according to claim 1, wherein the content of ceresin is 0.1 to 5 parts by mass with respect to 1 part by mass of polyglyceryl monooleate.
JP2015512517A 2013-04-19 2014-04-17 Emulsified composition Pending JPWO2014171507A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013088024 2013-04-19
JP2013088024 2013-04-19
PCT/JP2014/060919 WO2014171507A1 (en) 2013-04-19 2014-04-17 Emulsified composition

Publications (1)

Publication Number Publication Date
JPWO2014171507A1 true JPWO2014171507A1 (en) 2017-02-23

Family

ID=51731443

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015512517A Pending JPWO2014171507A1 (en) 2013-04-19 2014-04-17 Emulsified composition

Country Status (3)

Country Link
JP (1) JPWO2014171507A1 (en)
TW (1) TW201509441A (en)
WO (1) WO2014171507A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6506951B2 (en) * 2014-11-26 2019-04-24 株式会社ダリヤ Skin cosmetics
JP6893758B2 (en) * 2015-09-02 2021-06-23 ライオン株式会社 W / O type emulsified composition
KR20210126563A (en) 2019-02-13 2021-10-20 미요시 유시 가부시끼가이샤 Compositions comprising organic ammonium salts

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5426337A (en) * 1977-07-28 1979-02-27 Kanebo Ltd W/o type creamy or milky lotion composition
JPS62266135A (en) * 1986-05-12 1987-11-18 Pola Chem Ind Inc Oil-in-water type emulsified composition
JP4538377B2 (en) * 2005-06-03 2010-09-08 マルホ株式会社 Water-in-oil emulsion composition

Also Published As

Publication number Publication date
WO2014171507A1 (en) 2014-10-23
TW201509441A (en) 2015-03-16

Similar Documents

Publication Publication Date Title
JP7384885B2 (en) Transdermal preparations containing COX inhibitors
US11154535B2 (en) Transdermal formulation containing COX inhibitors
JPWO2014171507A1 (en) Emulsified composition
JP3593716B2 (en) Hemorrhoid treatment composition
JP5965187B2 (en) Oily ointment
US10045965B2 (en) Transdermal formulation containing COX inhibitors
JP5662495B2 (en) Pharmaceutical composition in solubilizer form
JP6031024B2 (en) Solid ointment containing prednisolone valerate acetate
JP2014111590A (en) Ointment
JP6077081B2 (en) Pharmaceutical composition
JP4731472B2 (en) Sustained release cream
JP6110839B2 (en) Pharmaceutical composition in solubilizer form
EP1541144A1 (en) Indometacin preparation for external use
JP2022096992A (en) Pharmaceutical composition for external use
JP6566574B2 (en) Ointment base and ointment
JP6067399B2 (en) Pharmaceutical composition
JP5730340B2 (en) Reservoir type pharmaceutical composition
JP2020055773A (en) Oily external liquid
JP2013535451A (en) Pharmaceutical composition having enhanced solubility characteristics
WO2008038806A1 (en) Antipruritic agent
JPWO2016181998A1 (en) Ophthalmic composition
JP2003040763A (en) Polyhydric alcohol-containing ointment base
OA17629A (en) Transdermal formulation containing COX inhibitors.